Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Inhibikase Therapeutics (IKT) Long-Term Debt Repayments (2021 - 2022)

Inhibikase Therapeutics (IKT) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $248911.0 as the latest value for Q1 2022.

Quarterly Long-Term Debt Repayments fell 39.24% to $248911.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $248911.0 through Dec 2022, up 485.2% year-over-year, with the annual reading at $248911.0 for FY2022, 485.2% up from the prior year.
Long-Term Debt Repayments for Q1 2022 was $248911.0 at Inhibikase Therapeutics, up from -$367128.0 in the prior quarter.
The five-year high for Long-Term Debt Repayments was $409662.0 in Q1 2021, with the low at -$367128.0 in Q2 2021.